JF
HRTX icon

Jump Financial’s Heron Therapeutics HRTX Stock Holding History

Jump Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,000
Closed -$44.3K – 2002
2024
Q1 		$44.3K Buy
+16,000
New +$40.2K ﹤0.01% 1833
2023
Q1 		– Sell
-80,266
Closed -$201K – 1783
2022
Q4 		$201K Buy
80,266
+13,355
+20% +$43K 0.01% 1288
2022
Q3 		$282K Buy
+66,911
New +$262K 0.01% 1177
2022
Q2 		– Sell
-29,161
Closed -$167K – 1792
2022
Q1 		$167K Buy
+29,161
New +$213K 0.01% 1345
2021
Q4 		– Sell
-70,326
Closed -$752K – 1527
2021
Q3 		$752K Buy
+70,326
New +$856K 0.05% 363
2021
Q2 		– Sell
-47,100
Closed -$763K – 1225
2021
Q1 		$763K Buy
+47,100
New +$840K 0.07% 293

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Jump Financial's HRTX Position: Q2 2024 in Review

Jump Financial sold out of Heron Therapeutics (HRTX) in Q2 2024, closing a stake of 16,000 shares — an estimated $44.3K sold.

Jump Financial first reported a position in HRTX in Q1 2021 and held it in 6 quarters. The position peaked at $763K in Q1 2021. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2024.

  • Jump Financial reported no remaining Heron Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Jump Financial sold 16,000 Heron Therapeutics shares in Q2 2024, an estimated $44.3K.
  • Jump Financial first reported a position in Heron Therapeutics in Q1 2021 and held it in 6 quarters.
  • Jump Financial's Heron Therapeutics position peaked at $763K in Q1 2021.
  • 190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2024.

Based on Jump Financial's 13F filing for Q2 2024, filed 14 Aug 2024.